Drugs / Vupanorsen
Vupanorsen
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04916795 | Jun → Oct 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04459767 | Aug → Dec 2020 | — | Pfizer | Completed | No outcome recorded |
| Phase 25 trials · 2 met primary | ||||||
| Phase 2 | NCT04516291 | Sep 2020 → Sep 2021 | hyperlipidemia, hyperlipoproteinemia | Pfizer | Completed | Met primary |
| Phase 2 | NCT03514420 | Jun 2018 → Jul 2019 | familial partial lipodystrophy | Akcea Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03455777 | Apr → Sep 2018 | homozygous familial hypercholesterolemia | Akcea Therapeutics | Withdrawn | No outcome recorded |
| Phase 2 | NCT03371355 | Dec 2017 → Nov 2019 | hypertriglyceridemia, metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus | Akcea Therapeutics | Completed | Met primary |
| Phase 2 | NCT03360747 | Dec 2017 → Jun 2018 | familial lipoprotein lipase deficiency, hypertriglyceridemia 1 | Akcea Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2021-11-24 | Pfizer | Results Pfizer Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia pfizer.com ↗
Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 2b study of vupanorsen (PF-07285557), an investigational antisense therapy being developed for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). |
| 2021-11-24 | Ionis Pharmaceuticals | Results Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen ionis.com ↗
In the dose-ranging study in subjects with elevated non-HDL-C and triglycerides (TG), the study met its primary endpoint, achieving a statistically significant reduction in non-HDL-C at all doses tested at 24 weeks, compared to placebo. |
| 2020-08-29 | Ionis Pharmaceuticals | Results Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020 ionis.com ↗ |
| 2020-01-28 | Ionis Pharmaceuticals | Results Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx ionis.com ↗ |
| 2017-05-25 | Ionis Pharmaceuticals | Results Akcea Announces Publication in The New England Journal of Medicine of Data with AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects ionis.com ↗
In the Phase 1/2 clinical study, treatment with AKCEA-ANGPTL3-LRx resulted in substantial, dose-dependent reductions in multiple lipids and lipoproteins, including triglycerides, LDL cholesterol, apolipoprotein B, non-HDL cholesterol and apolipoprotein C-III. |
All press releases naming this drug 13 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vupanorsen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04916795 ↗ |
| Known as | AKCEA-ANGPTL3-LRx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03514420 ↗ |
| Known as | ISIS 703802 | “Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)” NCT03455777 ↗ |
| Known as | PF-07285557 | “This is a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy, safety, tolerability, and pharmacokinetics (PK) of...” NCT04516291 ↗1“Vupanorsen (PF-07285557) is a second-generation tri-N-acetyl galactosamine (GalNAc3 )-antisense oligonucleotide targeted to angiopoietin-like 3 (ANGPTL3) mRNA” PMID 37002654 ↗ Mar 2023 |
| Action | Inhibit | “inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis” PMID 35369705 ↗ Apr 2022 |
| Modality | Antisense oligonucleotide | “second-generation tri-N-acetyl galactosamine (GalNAc3 )-antisense oligonucleotide” PMID 37002654 ↗ Mar 2023 |
| Route | Subcutaneous | “administered via SC injection QW” NCT03360747 ↗ |
| Target | ANGPTL3 | “targeted to angiopoietin-like 3 (ANGPTL3) mRNA” PMID 37002654 ↗ Mar 2023 |
| Target | ASGR1 | “Asialoglycoprotein receptor 1 binding agent” CHEMBL4298197 ↗ |